Birte Friedrichs

ORCID: 0000-0003-0945-2428
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • T-cell and Retrovirus Studies
  • Glycosylation and Glycoproteins Research
  • Viral-associated cancers and disorders
  • Cell Adhesion Molecules Research
  • Immune Cell Function and Interaction
  • CNS Lymphoma Diagnosis and Treatment
  • Eosinophilic Disorders and Syndromes
  • Immunotherapy and Immune Responses
  • Sociology and Education Studies
  • Polyomavirus and related diseases
  • Monoclonal and Polyclonal Antibodies Research
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Cutaneous lymphoproliferative disorders research
  • Education Methods and Technologies
  • Biosimilars and Bioanalytical Methods
  • T-cell and B-cell Immunology
  • Autoimmune and Inflammatory Disorders Research
  • Toxin Mechanisms and Immunotoxins
  • Viral Infectious Diseases and Gene Expression in Insects
  • Acute Lymphoblastic Leukemia research

University of Tübingen
2024

University Hospital Münster
2018-2024

Miltenyi Biotec (Germany)
2022-2023

Klinik für Schlafmedizin
2020

Klinik und Poliklinik für Psychosomatik und Psychotherapie
2019

Charité - Universitätsmedizin Berlin
2008-2014

Humboldt-Universität zu Berlin
2011

Freie Universität Berlin
2011

Asklepios Klinik St. Georg
2005-2010

Franklin University
2010

Haploidentical stem cell transplantation (haploSCT) offers an alternative treatment option for advanced leukemia patients lacking a HLA‐compatible donor. Transfer of NK cells represents promising therapeutic in combination with SCT, as can promote graft versus low risk GVH disease. In this study, we show results from phase I/II trial which 24 acute myeloid underwent haploSCT early transfer unmodified and observed 2‐year overall survival rate 37%. By performing immunomonitoring subsequent...

10.1002/eji.201444586 article EN European Journal of Immunology 2014-06-04

The oncofetal Ag immature laminin receptor (OFA-iLR) is a potential target molecule for immunotherapeutic studies in several tumor entities, including hematological malignancies. In the present study, we characterize two HLA-A*0201-presented epitopes eliciting strong OFA-iLR peptide-specific human cytotoxic T cell (CTLs) responses vitro. Both allogeneic HLA-A*0201-matched and autologous CTLs recognized killed endogenously OFA-iLR-expressing lines primary malignant cells from patients with...

10.4049/jimmunol.176.11.6935 article EN The Journal of Immunology 2006-06-01

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. Primary analysis of phase III randomized AATT study showed younger patients with peripheral T-cell lymphoma (PTCL)...

10.1200/jco.24.00554 article EN Journal of Clinical Oncology 2024-09-13

Lymphomatoid granulomatosis (LG) is a very rare, Epstein-Barr virus–associated lymphoproliferative disorder of B cells. Prognosis poor, particularly after relapse and no curative treatment exists. We report the results high-dose therapy autologous stem cell transplantation (ASCT) or reduced-intensity conditioning allogeneic (alloSCT) in patients with multiply relapsed LG. A European Group for Blood Marrow Transplantation survey identified 10 who had received 9 ASCT 4 alloSCT. All active...

10.1016/j.bbmt.2013.07.023 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2013-08-13

Abstract Chronic lymphocytic leukemia (CLL) is characterized by a highly variable clinical course. The role of an autologous tumor-specific immune control contributing to the length survival in CLL poorly understood. We investigated whether humoral immunity specific for CLL-associated Ag oncofetal Ag/immature laminin receptor (OFA/iLR) has prognostic value CLL. Among sera 67 untreated patients with CLL, 23 (34.3%) had detectable OFA/iLR Abs that were reactive at least one epitope. Patients...

10.4049/jimmunol.180.9.6374 article EN The Journal of Immunology 2008-05-01

7503 Background: In patients (pts) with peripheral T-cell lymphoma (PTCL) results of first-line therapy remain poor; guidelines recommend consolidation autologous transplantation (autoSCT) in transplant-eligible pts. AATT (Autologous or Allogeneic Transplantation lymphoma) sought to improve and compared alloSCT autoSCT. Methods: This was a prospective randomized trial comparing autoSCT younger pts (18-60 yrs) newly diagnosed PTCL who had achieved CR, PR, SD after 4 courses CHOEP 1 course...

10.1200/jco.2019.37.15_suppl.7503 article EN Journal of Clinical Oncology 2019-05-20

Summary To further improve outcome in young high‐risk patients with diffuse large B‐cell lymphoma ( DLBCL ) the number of rituximab (R) infusions was doubled combination standard CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone) chemotherapy. Seventy‐seven (aged 18–60 years) an age‐adjusted International Prognostic Index 2–3 received 12 × R (375 mg/m 2 on days 0, 1, 4, 8, 15, 22, 29, 43, 57, 71, 85 and 99 together eight cycles ‐14. Results were retrospectively...

10.1111/bjh.15710 article EN British Journal of Haematology 2018-12-05

Introduction: Elderly patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) represent a distinct patient population often limited treatment options. CAR-T cell can offer curative approach to this comorbid population, but data directly comparing standard chemotherapy therapy are scarce. MB-CART2019.1 (Zamtocabtagene autoleucel) is tandem product targeting CD20 and CD19 manufactured in 12-day process, vein-to-vein time of 14 days. was introduced Phase I dose finding...

10.1002/hon.3166_ot20 article EN Hematological Oncology 2023-06-01

This retrospective study examined the role of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) in stage-related therapy follicular lymphomas (FL). Twelve patients each stages I and II, 13 stage III 11 IV were treated Department Radiation Oncology, University Hospital Muenster, Germany from 2004 to 2016. Radiotherapy (RT), as well additional chemoimmunotherapy analyzed with a median follow-up 87.6 months. Ultrasound (US), CT 18F-FDG-PET/CT used...

10.3390/biomedicines9050561 article EN cc-by Biomedicines 2021-05-17

Drug Prescribing for Patients with Chronic Kidney Disease in General Practice: a Cross-Sectional Study

10.1055/s-0030-1263326 article EN DMW - Deutsche Medizinische Wochenschrift 2010-09-01

The aim of this study was to differentiate between types bipolar disorders and the associated features using explorative analysis. focus particularly on role 1 2 as well influence prophylactic interventions for relapse in a randomized, controlled treatment study. A total 274 305 originally included persons could be investigated Patients participated either cognitive behavioral group therapy (SEKT) or supportive, patient-centered (FEST). Treatment took place over 4 days separated by 1-month...

10.1007/s00115-024-01720-7 article EN cc-by Der Nervenarzt 2024-08-22

This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, first a t(10;11)(p11.2;q23) with MLL-AF10 and second t(11;19)(q23;p13.1) MLL-ELL fusion. They achieved remission under conventional chemotherapy but relapsed shortly after end therapy. history invasive mycoses (one possible pulmonary mycosis, one systemic candidiasis). Because no HLA-identical donor was available, haploidentical transplantation performed in both cases. Using...

10.1186/2162-3619-1-6 article EN cc-by Experimental Hematology and Oncology 2012-04-18

Der Klassenrat gilt als zentrales Element einer demokratischen Schulentwicklung. Sein Potenzial ist jedoch noch lange nicht ausgeschöpft. Welche zusätzlichen Möglichkeiten bietet er? Und wo liegen seine Grenzen?

10.3262/paed2210012 article DE Pädagogik 2022-09-30
Coming Soon ...